Skip to main content

Table 2 Prevalence and cumulative incidence at 6 years of allergy related diseases, wheeze and lower respiratory tract infections in the probiotic and placebo groups

From: Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial

  Imputed estimates Observed cases
Allergy related disease Probiotic, n=211 Placebo, n=204 Odds ratio (95 % CI)a Probiotic Placebo Odds ratio
  % (95 % CI) % (95 % CI)   n/n % (95 % CI) n/n % (95 % CI) (95 % CI)a
Current disease       
 Asthma 2.3 (0.0-4.7) 0.9 (0.0-2.5) 1.68 (0.21-13.20) 3/136 2.2 (0.7-6-7) 1/145 0.7 (0.0-4.8) 3.25 (0.33-31.6)
 Allergic sensitisation 30.0 (21.2-38.8) 28.0 (18.8-37.1) 1.11 (0.62-1.96) 23/80 28.8 (19.7-39.8) 19/78 24.4 (16.0-35.3) 1.25 (0.62-2.54)
Cumulative incidence         
  Atopic dermatitis 29.3 (21.2-37.4) 39.1 (30.2-48.0) 0.64 (0.39-1.07)b 22/81 27.2 (17.3-37.1) 36/82 43.9 (32.9-54.9) 0.48 (0.25-0.92)c
  ARC 21.6 (14.6-28.6) 18.8 (12.0-25.7) 1.19 (0.66-2.16) 22/134 16.4 (10.1-22.8) 20/145 13.8 (8.1-19.5) 1.22 (0.64-2.37)
  Wheeze 39.0 (30.9-47.1) 45.8 (37.4-54.1) 0.75 (0.47-1.22) 46/132 34.9 (26.7-43.0) 55/142 38.7 (30.7-46.8) 0.85 (0.52-1.38)
  LRTI (any) 30.6 (22.2-39.1) 36.8 (29.1-44.5) 0.76 (0.47-1.23) 33/128 25.8 (18.1-33.4) 40/138 29.0 (21.4-36.6) 0.85 (0.50-1.46)
  Bronchitis 23.6 (16.3-30.9) 27.6 (20.2-35.0) 0.81 (0.48-1.36) 29/130 22.3 (15.1-29.5) 32/139 23.0 (16.0-30.1) 0.96 (0.54-1.70)
  Pneumonia 10.2 (4.5-15.9) 15.4 (9.4-21.4) 0.61 (0.29-1.32) 7/129 5.4 (1.5-9.4) 17/141 12.1 (6.6-17.5) 0.42 (0.17-1.04)d
  1. ARC: allergic rhinoconjunctivitis; LRTI: Lower respiratory tract infection; aUnadjusted logistic regression odds ratio; Significant or near significant p-values: bp=0.086, cp=0.027 and dp=0.062